Vanguard Global Advisers
SER icon

Vanguard Global Advisers’s Serina Therapeutics SER Stock Holding History

Vanguard Global Advisers’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-368
Closed -$714 – 3748
2026
Q1 		$714 Buy
+368
New +$810 ﹤0.01% 3646

Other funds holding SER

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WA
Waverly Advisors Birmingham, Alabama $17.2B AUM 24.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AWE
Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Vanguard Global Advisers's SER Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Serina Therapeutics (SER) in Q2 2026, closing a stake of 368 shares — an estimated $714 sold.

Vanguard Global Advisers first reported a position in SER in Q1 2026 and held it in 1 quarter. The position peaked at $714 in Q1 2026. 27 funds tracked by Wall St. Rank hold SER as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Serina Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 368 Serina Therapeutics shares in Q2 2026, an estimated $714.
  • Vanguard Global Advisers first reported a position in Serina Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Serina Therapeutics position peaked at $714 in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.